Tiny UK Biotech Takes On Glaxo’s $730000 Gene Therapy – Bloomberg
Bloomberg |
Tiny UK Biotech Takes On Glaxo's $730000 Gene Therapy
Bloomberg Glaxo was hailed as a pioneer for its work to develop Strimvelis, just the second gene therapy for an inherited disease to gain approval. Now CEO Emma Walmsley is pruning likely duds from the company's pipeline of drugs and is seeking a partner for its … Tiny Biotech Takes on Goliath Glaxo's $730000 Gene Therapy |
